The high complete remission (CR) rates were obtained in both pediatric and adult r/r B‐ALL patients treated by either CD19‐directed (81%–90%) or CD22‐directed (73%–80%) CAR‐T cells.1, 2, 3, 4, 5, 6. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.